Core Viewpoint - Viesheng Pharmaceutical-B (02561) has seen a significant stock price increase, with a rise of over 9% during trading, currently at 37.24 HKD, driven by the anticipated approval of its core product, Lonapegsomatropin, expected on January 12, 2026 [1] Company Summary - Lonapegsomatropin is a long-acting growth hormone prodrug developed by Viesheng Pharmaceutical-B, licensed from Ascendis Pharma, utilizing TransCon technology for the treatment of Growth Hormone Deficiency (GHD) in children [1] - The product is designed for weekly subcutaneous injection, releasing unmodified natural growth hormone, and has already received approval in Europe and the United States [1] Industry Summary - The domestic growth hormone market primarily consists of daily formulations, while weekly formulations like Lonapegsomatropin are expected to significantly enhance patient compliance [1] - The introduction of Lonapegsomatropin is anticipated to reshape the competitive landscape and address unmet clinical needs in the market [1]
港股异动 | 维昇药业-B(02561)盘中涨超9% 核心产品隆培促生长素预计即将获批